TKM-Ebola
TKM-Ebola
TKM-Ebola (/tiːkeɪɛmːiːboʊlə/), also known as TKM-130803, is an experimental treatment for the Ebola virus disease. It is developed by Tekmira Pharmaceuticals, a Canadian biopharmaceutical company.
Etymology
The name TKM-Ebola is derived from the initials of the company that developed it, Tekmira Kinetic Medicine, and the disease it is designed to treat, Ebola.
Description
TKM-Ebola is a type of RNA interference (RNAi) therapeutic, which works by inhibiting the replication of the Ebola virus within the host's cells. It is composed of small interfering RNAs (siRNAs) that are encapsulated in lipid nanoparticles.
Development and Use
The development of TKM-Ebola began in the early 2000s, in response to the increasing global threat of the Ebola virus. It was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in 2014, during the West Africa Ebola outbreak.
Despite its experimental status, TKM-Ebola has been used under emergency protocols to treat a small number of patients with Ebola virus disease.
Related Terms
See Also
External links
- Medical encyclopedia article on TKM-Ebola
- Wikipedia's article - TKM-Ebola
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski